Comparison of the Diagnostic Accuracy of Next Generation Sequencing and Microarray Resequencing Methods for Detection of BRCA1 and BRCA2 Gene Mutations
AbstractObjective: Breast cancer constitutes 29 % of estimated new cases of cancer in women, and it is also one of the major cause of death in all cancer types. In this study, DNA samples of familial breast cancer patients with BRCA1 and BRCA2 mutations which had been analyzed using conventional DNA sequencing method, were also analyzed with new methods including microarray and next generation sequencing (NGS) in order to compare their results Methods: Seven patients with BRCA1 mutation, one patient with BRCA2 mutation, and two controls were included. All samples for the microarray method were studied on the GeneChip 3000 Scanner (Affymetrix) system and then analyzed on the Affymetrix GeneChip Resequencing Analysis Software (GSEQ® v4.0) system. Four patients from the patient group were selected for next generation sequencing and were analyzed on GS Junior 454 (Roche, Prague, Czech Republic) system. The raw data had been analysed by SeqPilot SeqNext module (v4.0, JSI medical systems, Kippenheim, Germany). Results: Microarray resequencing analysis did not detect the mutations defined by conventional sequencing in patients, but mutations were detected in all of the 4 patients in the next generation sequencing. Conclusion: Our study detected the NGS to be reliable as conventional DNA sequencing for studying BRCA1/BRCA2 gene mutations. However, we suggest to confirm the NGS results with a conventional method because of homopolymer sequences which may cause false positive results.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J. Clin. 2016; 66: 7-30.
Kast K, Rhiem K, Wappenschmidt B, Hahnen E, Hauke J, Bluemcke B, et al. Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. J. Med. Genet. 2016; 53: 465-71.
Stenson PD, Mort M, Ball EV, Evans K, Hayden M, et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum. Genet. 2017; 136: 665-77.
Lebet T, Chiles R, Hsu AP, Mansfield ES, Warrington JA, Puck JM. Mutations causing severe combined immunodeficiency: detection with a custom resequencing microarray. Genet. Med. 2008; 10: 575-85.
Hernan I, Borràs E, de Sousa Dias M, Gamundi MJ, Mañé B, Llort G, et al. Detection of genomic variations in BRCA1 and BRCA2 genes by long-range PCR and next-generation sequencing. J. Mol. Diagn. 2012; 14: 286-93.
Lynch HT, Silva E, Snyder C, Lynch JF. Hereditary breast cancer: part I. Diagnosing hereditary breast cancer syndromes. Breast J. 2008; 14: 3-13.
Rouleau E, Lefol C, Tozlu S, Andrieu C, Guy C, Copigny F, et al. High‐resolution oligonucleotide array‐CGH applied to the detection and characterization of large rearrangements in the hereditary breast cancer gene BRCA1. Clin. Genet. 2007; 72: 199-207.
Pollack JR, Sørlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc. Natl. Acad. Sci. U S A. 2002; 99: 12963-8.
Mardis ER. The impact of next-generation sequencing technology on genetics. Trends Genet. 2008; 24: 133-41.
Shen T, Pajaro-Van de Stadt SH, Yeat NC, Lin JC-H. Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. Front. Genet. 2015; 6: 215.
All opinions and reports within the articles that are published in the Gazi Medical Journal are the personal opinions of author(s). Gazi University, Editors and the publisher do not accept any responsibility for these articles. The journal is printed on acid-free paper.